Antibacterial Agents TRIZ Cases

Hydrolyzed carob peptides activate aquaporin 3 expression to correct chronic skin dehydration and restore barrier function.

Cationic dendrimers inhibit bacterial efflux pumps, reducing minimum inhibitory concentration and overcoming antibiotic resistance without increasing toxicity.

Composite Trigonella foenum-graecum extract combats resistant bacterial strains through multi-component synergy.

Mechanical scarification enables low-dose viral vector delivery to epidermis, resolving weak T-cell responses from conventional injections.

Exosomes deliver protective microRNAs to treat sepsis, resolving the trade-off between therapeutic efficacy and treatment complexity.

Azetidine derivatives target CB1 receptors to address gaps in treating psychiatric and neurodegenerative diseases.

Transition state analogues inhibit H. pylori MTAN enzyme, blocking the menaquinone pathway to overcome antibiotic resistance.

Self-emulsifying formulations overcome poor aqueous solubility of lipophilic antifungals by forming fine emulsions that boost bioavailability.

A synthetic carba-analogue serogroup A antigen enables a fully liquid pentavalent vaccine formulation.

Adding Hydroxy-Alkyl-Cellulose stabilizes ethanol concentration against humidity, preventing rapid dilution during delayed ignition.

Thia-triaza-cyclopentazulene compounds resolve inadequate cell proliferation control by inhibiting mTOR-induced p-4E-BP1 phosphorylation.

WH-21091 macrocyclic amides overcome bacterial resistance to conventional antibiotics by utilizing symbiotic bacteria fermentation for novel drug development.

Ad11p adenovirus vectors target neural and carcinoma cells with high infectivity while evading population seroprevalence.

Encapsulating antibiotics in a calcium cement matrix sustains release, reducing cytotoxicity and preventing bacterial colonization.

Combining distinct enzymatic domains on separate polypeptides enhances antimicrobial activity and thermostability.

Minimal N-terminal methionine extension simplifies recombinant histone purification while preserving biological activity.

Formula X bicyclic and tricyclic compounds inhibit the KAT II enzyme, reducing KYNA synthesis to treat cognitive deficits associated with schizophrenia.

Alkylthio-substituted 2-methylthiopyrrolidines disrupt Pseudomonas aeruginosa communication to prevent biofilm formation and resistance.

Simplified carbapenem crystallization process yields stable formulations without lyophilization.

Methyl-4-O-[β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl]-3,5-dimethoxybenzoate serves as a specific chemical marker for bioactivity assessment.

Synthetic nanocarriers stimulate potent antibody production without requiring T-cell antigens.

Trivalent Salmonella vaccine reduces infection shedding by combining serogroups B, D, and C1 or C2-3 while minimizing antigen interference.

A cationic nanogel composite delivers vaccine antigens via the nasal mucosa to induce robust systemic and mucosal immune responses.

Alkaline pH adjustment enables selective lactoferrin binding to cation exchange resin, eliminating defatting steps while maintaining protein integrity.

Humanized antagonist anti-CD40 antibodies block the CD40/CD40L interaction to treat chronic inflammatory diseases where TNF inhibitors fail.

New beta-lactamase inhibitor compounds featuring aromatic rings extend half-life and reduce clearance rates.

A nitrogen-containing five-membered ring compound accelerates human antimicrobial peptide secretion through selective molecular activation.

Aluminium hydroxyphosphate adjuvants adsorb fHBP antigens via pH control, resolving antigen degradation issues found with aluminium hydroxide.

Engineered human antibodies target the IL-4 receptor alpha chain to block interleukin-4 and interleukin-13 signaling while minimizing cross-reactivity.

Attenuated bacteria expressing IpaB or SipB induce apoptosis in tumor-associated macrophages, depleting immune evasion mechanisms.

L19 ribosomal protein induces endogenous anti-inflammatory cytokines to treat inflammatory disorders without systemic side effects.

Cochleate compositions encapsulate pharmacologically active agents within phospholipid bilayers to enhance tissue penetration.

Free fatty acids stimulate bowel movements via nociceptor activation, eliminating abdominal discomfort and cramps associated with conventional laxatives.

Plasmonic nanoparticles enable targeted skin thermomodulation, resolving the trade-off between treatment efficacy and non-specific tissue damage.

Carbon nanostructure bacteriophage injects medication directly into the cytosol via a dedicated transport channel.

Novel rifamycin congeners inhibit RNA polymerase activity to treat bacterial infections.

SP1 and SP2 polypeptides overcome poor capsular immunogenicity to provide broad serotype protection.

Conjugating ETEC recombinant polypeptides to C. jejuni capsule polysaccharides resolves pathogen coverage complexity while avoiding autoimmune risks.

A pleuromutilin conjugate featuring a triazole-based side-group attached via a carbonyl linker to an aromatic ring.

Engineered molecular sleds slide along DNA tracks to transport AVP-pVIc complexes, resolving diffusion bottlenecks caused by high genomic density.

Biparatopic polypeptides block the Type III Secretion System, overcoming antibiotic resistance in chronic infections.

ALB408-423 polypeptide binds CXCR4 receptors, blocking viral entry and suppressing cancer cell migration without inducing cytotoxicity.

A sulfonic acid formulation desiccates necrotic tissue and biofilms to promote wound healing.

Combining neuraminidase inhibitors with matrix metalloproteinase down-regulators to prevent extracellular matrix destruction and secondary bacterial sepsis.

Clotrimazole treats methicillin-resistant Staphylococcus infections by bypassing conventional antibiotic resistance pathways.

A composition with polymeric cationic antimicrobials removes spores from skin through mechanical action.